Immatics To Go Public Through Merger With ‘Blank Check’ Company Arya

 
• By Joseph Haas
  
T Cell lymphocyte with receptors for cancer cell immunotherapy research 3D render
Immatics now will have a public listing and plenty of cash to advance its TCR pipeline
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business